Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1964 1
1966 1
2000 1
2005 3
2006 4
2007 3
2008 3
2009 2
2010 4
2011 3
2012 4
2013 4
2014 6
2015 9
2016 11
2017 8
2018 10
2019 5
2020 10
2021 7
2022 10
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, Atduev V, Buchschacher GL Jr, Gafanov R, Corrales L, Borre M, Stroyakovskiy D, Alves GV, Bournakis E, Puente J, Harle-Yge ML, Gallo J, Chen G, Hanover J, Wongchenko MJ, Garcia J, de Bono JS. Sweeney C, et al. Among authors: corrales l. Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8. Lancet. 2021. PMID: 34246347 Clinical Trial.
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF, Cardona AF, Rodríguez J, Ruiz-Patiño A, Arrieta O, Moreno-Pérez DA, Rojas L, Zatarain-Barrón ZL, Ardila DV, Viola L, Recondo G, Blaquier JB, Martín C, Raez L, Samtani S, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Archila P, Bermudez M, Gamez T, Russo A, Malapelle U, de Miguel Perez D, de Lima VCC, Freitas H, Saldahna E, Rolfo C, Rosell R; CLICaP. Chamorro DF, et al. Among authors: corrales l. Target Oncol. 2023 May;18(3):425-440. doi: 10.1007/s11523-023-00955-9. Epub 2023 Apr 5. Target Oncol. 2023. PMID: 37017806 Free PMC article.
LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ. Corrales L, et al. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. eCollection 2022. Front Immunol. 2022. PMID: 36159851 Free PMC article.
Innate immune recognition of cancer.
Woo SR, Corrales L, Gajewski TF. Woo SR, et al. Among authors: corrales l. Annu Rev Immunol. 2015;33:445-74. doi: 10.1146/annurev-immunol-032414-112043. Epub 2015 Jan 22. Annu Rev Immunol. 2015. PMID: 25622193 Review.
The role of complement in tumor growth.
Pio R, Corrales L, Lambris JD. Pio R, et al. Among authors: corrales l. Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11. Adv Exp Med Biol. 2014. PMID: 24272362 Free PMC article. Review.
105 results